Skip to content

Xencor XNCR Net Investment in Lease

Net Investment in Lease at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
Absci Corporation logo
Absci CorporationABSI
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's net investment in lease?
Xencor (XNCR) reported net investment in lease of $36.82M in Q1 2026.
How has Xencor's net investment in lease changed year-over-year?
Xencor's net investment in lease decreased by 2.2% year-over-year, from $37.65M to $36.82M.
What is the long-term trend for Xencor's net investment in lease?
Over 5 years (2020 to 2025), Xencor's net investment in lease has grown at a 28.8% compound annual growth rate (CAGR), from $10.6M to $37.59M.